KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Short term Debt (2016 - 2026)

Idexx Laboratories has reported Short term Debt over the past 17 years, most recently at $75.0 million for Q4 2025.

  • For Q4 2025, Short term Debt fell 55.3% year-over-year to $75.0 million; the TTM value through Dec 2025 reached $75.0 million, down 55.3%, while the annual FY2025 figure was $75.0 million, 55.3% down from the prior year.
  • Short term Debt for Q4 2025 was $75.0 million at Idexx Laboratories, down from $150.0 million in the prior quarter.
  • Over five years, Short term Debt peaked at $633.0 million in Q3 2022 and troughed at $73.5 million in Q4 2021.
  • A 5-year average of $207.9 million and a median of $158.9 million in 2024 define the central range for Short term Debt.
  • Biggest five-year swings in Short term Debt: crashed 74.33% in 2021 and later soared 744.11% in 2022.
  • Year by year, Short term Debt stood at $73.5 million in 2021, then skyrocketed by 240.14% to $250.0 million in 2022, then tumbled by 70.0% to $75.0 million in 2023, then surged by 123.72% to $167.8 million in 2024, then plummeted by 55.3% to $75.0 million in 2025.
  • Business Quant data shows Short term Debt for IDXX at $75.0 million in Q4 2025, $150.0 million in Q3 2025, and $579.0 million in Q2 2025.